UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma

UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma

Voxtalisib, is a specific, effective, and reversible dual inhibitor, which inhibits both pan-class I phosphoinositide 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR). To date, voxtalisib has been studied in trials for melanoma, lymphoma, glioblastoma, breast cancer, and other cancers. In...

Full description

Bibliographic Details
Main Authors: Qingqing Li, Ya-nan Liu, Jing Wang, Yingying Hu, Jinyu Hu, Ren-ai Xu, Liu Shao, Lianguo Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Pharmacology
Subjects:
voxtalisib
quantitative methodology
pharmacokinetic analysis
UPLC-MS/MS technology
rat plasma
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.914733/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.914733/full

Similar Items